Teprotumumab for thyroid eye disease study
Part of Eyes & vision, Genetic & congenital, Hormones & metabolism, Immune system & allergy clinical trials.
This study tests if the drug teprotumumab can help with symptoms of thyroid eye disease, such as bulging eyes, pain, or double vision. It is for adults who are beneficiaries of the Department of Defense (DOD).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be a DOD beneficiary (such as active duty, retiree, or family member).
- You must be 18 years or older.
- You must have symptoms of thyroid eye disease like bulging eyes, eye pain, double vision, or eyelid swelling or redness.
- You must not have severe vision loss from pressure on the optic nerve that needs emergency surgery or radiation.
- You must not have uncontrolled diabetes or uncontrolled inflammatory bowel disease.
- You must not be pregnant or trying to become pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a drug called teprotumumab for people with active thyroid eye disease. It is designed to help reduce eye bulging and other symptoms, and may be an option if you have not had strong treatments before.
This trial tests a new version of an antibody treatment (teprotumumab) for people with active thyroid eye disease. It aims to reduce bulging and inflammation of the eyes, and you must have had symptoms for less than 9 months to join.
This trial compares two different lengths of treatment with Tepezza (teprotumumab) for thyroid eye disease. It aims to see if 4 treatments are as effective and safe as 8 treatments, which could mean fewer infusions for patients who respond early.
This trial compares a newer medication (teprotumumab) with standard steroid treatment for people with thyroid eye disease and vision loss who are about to have urgent surgery to relieve pressure on the optic nerve. The goal is to see which approach better protects and restores vision after surgery.
This trial tests a new medicine (veligrotug) for people with thyroid eye disease whose symptoms returned after completing teprotumumab. It aims to see if veligrotug can help again.
This trial tests a new medicine (KHN939) for people with moderate-to-severe active thyroid eye disease. If you qualify, the study may help reduce bulging eyes and double vision.
Hear when a new Graves Ophthalmopathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.